| Source: |
| Type: |
| Normal cells grow and divide in a regulated manner through the cell cycle, which consists of phases (G1, S, G2, and M). Cancer cells often bypass these regulatory mechanisms, leading to uncontrolled proliferation. This can result from mutations in genes that control the cell cycle, such as oncogenes (which promote cell division) and tumor suppressor genes (which inhibit cell division). |
| Lung CSC (Cancer Stem Cells) markers (CD133, CD44, ALDHA1, Nanog and Oct4) |
| 2432- | 2DG, | Inhibition of glycolytic enzyme hexokinase II (HK2) suppresses lung tumor growth |
| - | in-vitro, | Lung, | H23 | - | in-vitro, | Lung, | KP2 | - | in-vivo, | NA, | NA |
| 4551- | AgNPs, | FBZ, | Ångstrom-Scale Silver Particles as a Promising Agent for Low-Toxicity Broad-Spectrum Potent Anticancer Therapy |
| - | in-vivo, | Lung, | NA |
| 379- | AgNPs, | Effects of green-synthesized silver nanoparticles on lung cancer cells in vitro and grown as xenograft tumors in vivo |
| - | in-vivo, | Lung, | H1299 |
| 280- | ALA, | Alpha‐lipoic acid inhibits lung cancer growth via mTOR‐mediated autophagy inhibition |
| - | in-vivo, | Lung, | A549 |
| 291- | ALA, | HCA, | MET, | DFC, | Metabolic therapies inhibit tumor growth in vivo and in silico |
| - | in-vivo, | Melanoma, | B16-F10 | - | in-vivo, | Lung, | LL/2 (LLC1) | - | in-vivo, | Bladder, | MBT-2 |
| 1349- | And, | Andrographolide promoted ferroptosis to repress the development of non-small cell lung cancer through activation of the mitochondrial dysfunction |
| - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | H1650 |
| 2476- | Ba, | Baicalein Induces Caspase-dependent Apoptosis Associated with the Generation of ROS and the Activation of AMPK in Human Lung Carcinoma A549 Cells |
| - | in-vitro, | Lung, | A549 |
| 2618- | Ba, | Baicalein induces apoptosis by inhibiting the glutamine-mTOR metabolic pathway in lung cancer |
| - | in-vitro, | Lung, | H1299 | - | in-vivo, | Lung, | A549 |
| 5543- | BBM, | Enhanced anti-metastatic and anti-tumorigenic efficacy of Berbamine loaded lipid nanoparticles in vivo |
| - | in-vivo, | Lung, | B16-F10 | - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-231 |
| 1030- | BBR, | Berberine diminishes cancer cell PD-L1 expression and facilitates antitumor immunity via inhibiting the deubiquitination activity of CSN5 |
| - | in-vitro, | Lung, | H460 |
| 1397- | BBR, | Chemo, | Effects of Coptis extract combined with chemotherapeutic agents on ROS production, multidrug resistance, and cell growth in A549 human lung cancer cells |
| - | in-vitro, | Lung, | A549 |
| 2702- | BBR, | The enhancement of combination of berberine and metformin in inhibition of DNMT1 gene expression through interplay of SP1 and PDPK1 |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1975 |
| 5636- | BCA, | Biochanin A Induces S Phase Arrest and Apoptosis in Lung Cancer Cells |
| - | vitro+vivo, | Lung, | A549 |
| 6497- | BCP, | Cisplatin, | Beta-Caryophyllene Enhances the Anti-Tumor Activity of Cisplatin in Lung Cancer Cell Lines through Regulating Cell Cycle and Apoptosis Signaling Molecules |
| - | in-vitro, | Lung, | NA |
| 5729- | BF, | Bufalin: a potential drug for regulating EGFR-TKIs resistance in lung cancer via the EGFR-PI3K/Akt-mTOR signaling |
| - | in-vitro, | Lung, | NA |
| 5695- | BRU, | Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism |
| - | in-vitro, | Lung, | A549 |
| 7173- | CHA, | Natural compound chaetocin induced DNA damage and apoptosis through reactive oxygen species-dependent pathways in A549 lung cancer cells and in vitro evaluations |
| - | in-vitro, | Lung, | A549 |
| 7163- | CHA, | The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | OS, | U2OS | - | in-vitro, | CRC, | HCT116 | - | in-vitro, | CRC, | HeLa | - | in-vivo, | Ovarian, | SKOV3 |
| 2793- | CHr, | Chrysin Inhibits TAMs-Mediated Autophagy Activation via CDK1/ULK1 Pathway and Reverses TAMs-Mediated Growth-Promoting Effects in Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H157 | - | in-vivo, | NA, | NA |
| 1574- | Citrate, | Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Melanoma, | WM983B | - | in-vivo, | NA, | NA |
| 6186- | Cuc, | Cucurbitacin Q: a selective STAT3 activation inhibitor with potent antitumor activity |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | BC, | MDA-MB-453 |
| 4676- | CUR, | Curcumin suppresses stem-like traits of lung cancer cells via inhibiting the JAK2/STAT3 signaling pathway |
| - | vitro+vivo, | Lung, | H460 |
| 404- | CUR, | Curcumin induces ferroptosis in non-small-cell lung cancer via activating autophagy |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | H1299 |
| 1876- | DCA, | Chemo, | In vitro cytotoxicity of novel platinum-based drugs and dichloroacetate against lung carcinoid cell lines |
| - | in-vivo, | Lung, | H727 |
| 6270- | DL, | d-limonene exhibits antitumor activity by inducing autophagy and apoptosis in lung cancer |
| - | vitro+vivo, | Lung, | A549 | - | vitro+vivo, | Lung, | H1299 |
| 6845- | EVO, | Evodiamine, a Novel NOTCH3 Methylation Stimulator, Significantly Suppresses Lung Carcinogenesis in Vitro and in Vivo |
| - | vitro+vivo, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 1022- | EVO, | Evodiamine suppresses non-small cell lung cancer by elevating CD8+ T cells and downregulating the MUC1-C/PD-L1 axis |
| - | in-vivo, | Lung, | H1975 | - | in-vitro, | Lung, | H1650 |
| 6853- | FBZ, | Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death by modulating multiple cellular pathways |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Lung, | H460 |
| 6969- | Form, | Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer |
| - | vitro+vivo, | NSCLC, | HCC827 | - | in-vitro, | NSCLC, | A549 | - | in-vitro, | Lung, | H1299 |
| 7043- | GA, | Gallic acid-induced lung cancer cell death is related to glutathione depletion as well as reactive oxygen species increase |
| - | in-vitro, | Lung, | Calu-1 | - | in-vitro, | Lung, | A549 |
| 1970- | GamB, | Gambogic acid-induced autophagy in nonsmall cell lung cancer NCI-H441 cells through a reactive oxygen species pathway |
| - | NA, | Lung, | NCI-H441 |
| 7063- | GamB, | Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells |
| - | vitro+vivo, | Lung, | H1299 |
| 7226- | GBE, | Ginkgo biloba exocarp extracts induces apoptosis in Lewis lung cancer cells involving MAPK signaling pathways |
| - | vitro+vivo, | Lung, | NA |
| 7139- | GI, | 6-Shogaol Exhibits a Promoting Effect with Tax via Binding HSP60 in Non-Small-Cell Lung Cancer |
| - | vitro+vivo, | Lung, | A549 | - | in-vitro, | Melanoma, | A375 | - | in-vitro, | GBM, | U251 |
| 7323- | GSE, | Grape seed procyanidin extract against lung cancer: the role of microrna-106b, bioavailability, and bioactivity |
| - | vitro+vivo, | Lung, | NA |
| 1021- | HNK, | Honokiol suppress the PD-L1 expression to improve anti-tumor immunity in lung cancer |
| - | in-vivo, | Lung, | NA |
| 1025- | LT, | Api, | Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer |
| - | in-vivo, | Lung, | NA |
| 1042- | MEL, | Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H460 | - | in-vitro, | Lung, | LLC1 |
| 2261- | MF, | Tumor-specific inhibition with magnetic field |
| - | in-vitro, | Nor, | GP-293 | - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 |
| 507- | MF, | Effects of extremely low frequency electromagnetic fields on the tumor cell inhibition and the possible mechanism |
| - | in-vitro, | Liver, | HepG2 | - | in-vitro, | Lung, | A549 | - | in-vitro, | Nor, | GP-293 |
| 227- | MFrot, | MF, | Low Frequency Magnetic Fields Induce Autophagy-associated Cell Death in Lung Cancer through miR-486-mediated Inhibition of Akt/mTOR Signaling Pathway |
| - | in-vivo, | Lung, | A549 | - | in-vitro, | Lung, | A549 |
| 222- | MFrot, | MF, | LF-MF inhibits iron metabolism and suppresses lung cancer through activation of P53-miR-34a-E2F1/E2F3 pathway |
| - | in-vitro, | Lung, | A549 |
| 1812- | Oxy, | Hyperbaric oxygen suppressed tumor progression through the improvement of tumor hypoxia and induction of tumor apoptosis in A549-cell-transferred lung cancer |
| - | in-vitro, | Lung, | A549 | - | in-vivo, | Lung, | NA | - | in-vitro, | NA, | BEAS-2B |
| 2074- | PB, | Chemo, | The effect of combined treatment with sodium phenylbutyrate and cisplatin, erlotinib, or gefitinib on resistant NSCLC cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | H1650 |
| 4955- | PEITC, | Phenethyl isothiocyanate-induced cytoskeletal changes and cell death in lung cancer cells |
| - | in-vitro, | Lung, | A549 | - | in-vitro, | Lung, | H1299 |
| 4956- | PEITC, | Inhibition of cancer growth in vitro and in vivo by a novel ROS-modulating agent with ability to eliminate stem-like cancer cells |
| - | vitro+vivo, | Lung, | A549 |
| 4930- | PEITC, | Targeted anti-cancer therapy: Co-delivery of VEGF siRNA and Phenethyl isothiocyanate (PEITC) via cRGD-modified lipid nanoparticles for enhanced anti-angiogenic efficacy |
| - | vitro+vivo, | Lung, | A549 |
| 1768- | PG, | Propyl gallate reduces the growth of lung cancer cells through caspase‑dependent apoptosis and G1 phase arrest of the cell cycle |
| - | in-vitro, | Lung, | Calu-6 | - | in-vitro, | Lung, | A549 |
| 1774- | PG, | Geno- and cytotoxicity of propyl gallate food additive |
| - | in-vitro, | Lung, | A549 |
| 2995- | PL, | Piperlongumine overcomes osimertinib resistance via governing ubiquitination-modulated Sp1 turnover |
| - | in-vitro, | Lung, | H1975 | - | in-vitro, | Lung, | PC9 | - | in-vivo, | NA, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:15 Cells:% prod#:% Target#:323 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid